Genetically engineered CD19-CAR T cells to secrete anti-CD47 scFv effectively enhance the polyfunctionality and tumor killing function of CAR T cells, uplifting their persistence and immune activity and facilitating their differentiation into naive phenotypes. This evidence concerns the gene CD47 and neoplasm.